Convergent abnormalities were observed in secondary analyses across portions of the amygdala, hippocampus, subgenual cingulate cortex, and putamen.
For patients with MDD, the change in scores for depression at six weeks does not differ significantly with psilocybin or psilocybin plus escitalopram.
Recently updated diagnostic criteria for fibromyalgia that reduce the underdiagnosis in men had not been implemented during these studies.
The study provides strong evidence for the utility of resting-state fMRI measures in predicting the development of attentional or mood disorders in children.
Patients with psychotic depression who experienced an illness relapse while receiving placebo also had a decline in cortical thickness, emphasizing the essential role antipsychotics play in treating disorders where psychosis is present.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Investigators posit that wearable devices will help psychiatrists to target mood and cognitive interventions.
This study highlights the importance of transdiagnostic approaches to psychiatry.
Anna S. Urrila, MD and colleagues sought to explore whether sleep symptoms in adolescents with MDD were associated with long-term outcomes.
Alzheimer's Disease and Dementia
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease agitation.